ARAnasuya Roychowdhury

Anasuya Roychowdhury

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anasuya Roychowdhury has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Sinjini Patra

    Biochemistry and Cell Biology Laboratory, School of Basic Sciences, Indian Institute of Technology Bhubaneswar, Bhubaneswar, India

    6 shared publications
  • Maria J. Jezewska

    Department of Biochemistry and Molecular Biology, Department of Obstetrics and Gynecology, Sealy Center for Structural Biology, and Sealy Center for Cancer Cell Biology, The University of Texas Medical Branch at Galveston, 301 University Boulevard, Galveston, Texas 77555-1053

    5 shared publications
  • Biswaranjan Pradhan

    S. K. Dash Center of Excellence of Biosciences and Engineering & Technology (SKBET), Indian Institute of Technology Bhubaneswar, Odisha, India

    4 shared publications
  • Michal R. Szymanski

    Department of Biochemistry and Molecular Biology, The University of Texas Medical Branch at Galveston, 301 University Boulevard, Galveston, TX 77555-1053, United States

    4 shared publications
  • Aditi Nayak

    Biochemistry and Cell Biology Laboratory, School of Basic Sciences, Indian Institute of Technology Bhubaneswar, Odisha 752050, India

    3 shared publications
  • Madhuri Dutta

    Biochemistry and Cell Biology Laboratory, School of Basic Sciences, Indian Institute of Technology Bhubaneswar, Odisha, 752050, India

    3 shared publications

Latest Publications

  • WGS analysis and functional studies illustrate promising gene-signatures for probiotic attributes and molecular-targeted therapeutic prospects of Lactiplantibacillus plantarum LP-ARP2

    by Sinjini Patra, Ritwik Patra, Pradeep Kumar Das, Anshuman Dixit, Anasuya Roychowdhury

    Gene-signatures for probiotic attributes expedite screening of novel probiotic strains as well as identify molecular basis of probiotic benefits. Therefore, strain-specific genomic-studies correlating functional-assays are in demand. Here, we present the same for Lactiplantibacillus plantarum LP-ARP2 using genomic-metabolomic-functional approaches. Genomic-features of LP-ARP2 are further compared with clinically relevant L. plantarum strains to elucidate gene-specific commonality. We find robust stress-resilience genetic set-up (usp/hsl/clp/ABC-transporters/ ATP-synthase/chaperons dna/gro/grp) in LP-ARP2-genome. Our acid/bile tolerance assays also indicate survivability (> 60%) of the strain in harsh conditions. Presence of adhesion-related (lspA/mapA/eno/srtA/glycosyltransferases/glycosylhydrolases/lipoproteins) and biofilm-forming genes (veg/luxS) further align with its efficacy in autoaggregation (> 60%), adhesion (Caco-2), and biofilm-formation (24 h). CAZyme-genes with significant prebiotic utilization indicate the strain’s ability for gut-microbial-modulation and adaptation. Metabolic-profiling of LP-ARP2-derived-CFS (HRMS analysis) validates the presence of related genes for SCFAs/vitamins/amino-acids/neurotransmitters GABA/serotonin/acetylcholine etc. Besides, many metabolites are reported antimicrobials. Indeed LP-ARP2 shows significant antibacterial potential against multidrug-resistant bacteria (Gram-positive/Gram-negative), gut-pathogen Salmonella Typhimurium and pathogenic-biofilm (MRSA). Presence of antioxidant-genes in LP-ARP2-genome (thioredoxin/NADH-dependent-nox/npr/ndh/glutathione-reductase/glutaredoxin/catalase/peroxidases/methionine sulfoxide reductase) are validated by high radical-scavenging activity of LP-ARP2 (ABTS > 40%, DPPH 25 U/mL, superoxide > 80%, and hydroxyl > 70%). Moreover, in-silico functional-network-analysis reveals LP-ARP2-derived metabolites target oxidative stress, neuroinflammation, amyloid-beta metabolism, tau-phosphorylation, neurogenesis, and synaptic function, indicating molecular relevance of the therapeutic potential of LP-ARP2. Fascinatingly, genomic-analysis between LP-ARP2 with clinically relevant (depression and intestinal disorders) L. plantarum strains (299v and Lp01) elucidate comparable genetic-features for beneficial probiotics. Thus, study offers potential gene-signatures for probiotic-benefits of L. plantarum and project LP-ARP2 as a promising probiotic with antibacterial, antioxidant and psychobiotic potential. Graphical Abstract


  • Open Access

    Complete genome sequence, metabolic profiling and functional studies reveal Ligilactobacillus salivarius LS-ARS2 is a promising biofilm-forming probiotic with significant antioxidant, antibacterial, and antibiofilm potential

    by Sinjini Patra, Biswaranjan Pradhan, Anasuya Roychowdhury

    Background: Probiotics restore microbial balance and prevent gut-inflammation. Therefore, finding out novel probiotic strains is a demand. As gut-microbe, benefits of Ligilactobacillus salivarius (LS) are established. However, strain-specific detailed studies are limited. Here, we illustrate probiotic attributes of novel LS-ARS2 for its potential application as food-supplement and/or therapeutic to improve gut-health.Methods: Whole genome sequencing (WGS) and phylogenetic analysis confirm the strain as LS. To establish probiotic properties, acid-bile tolerance, auto-aggregation, cell-surface-hydrophobicity, biofilm-formation, and adhesion-assays are performed. To ensure safety attributes, antibiotic-susceptibility, hemolytic, DNase, trypan-blue, and MTT assays are done. ABTS, DPPH, superoxide, hydroxyl free radical scavenging assays are used to determine anti-oxidant potential. Antibacterial assays, including co-culture assay with pathogen and pathogenic biofilm-inhibition assays, are performed to explore antibacterial efficacy. To characterize metabolic-profile of LS-ARS2-derived cell-free-supernatant (CFS), HRMS analysis are carried out. Consequently, WGS-analyses predict potential molecular associations related to functional outcomes.Results: We find LS-ARS2 a remarkable fast-growing strain that shows acid and bile tolerance (>60% survival rate), indicating promising gut-sustainability. High auto-aggregation capacity (>80%), robust cell-surface hydrophobicity (>85%), and adhesion efficacy to Caco-2 cells illustrate significant potential of LS-ARS2 for gut colonization. Fascinatingly, LS-ARS2 is able to form biofilm within 24 h (p < 0.0001), rare among LS strains, indicating the potential of the strain for efficient stay in the gut. The strain ensures safety attributes. LS-ARS2-WGS analysis recognizes probiotic-specific determinants, predicts genomic stability, identifies orthologous-clusters for diverse functions, and predicts metabolites and bacteriocins. HRMS-studies with LS-ARS2-CFS further validate the presence of diverse beneficial metabolites with antimicrobial and immunomodulatory potential. LS-ARS2 shows significant antioxidant properties in ABTS (>60%), DPPH (>10 U/mL), superoxide (>70%), and hydroxyl free radical scavenging assays (>70%). Further, LS-ARS2 shows antimicrobial activities against Gram-positive Methicillin-resistant Staphylococcus aureus (MRSA) and Gram-negative multidrug-resistant clinical strains enterotoxigenic Escherichia coli, Vibrio cholerae, and Shigella flexneri. Anti-Salmonella effect of LS-ARS2 is prominent (p < 0.0001). Most interestingly, LS-ARS2-CFS inhibits MRSA-biofilm (p < 0.0001), again rare among LS strains.Conclusion: LS-ARS2 is a novel, fast-growing, biofilm-forming probiotic with significant antioxidant, antibacterial, and anti-biofilm potentials, suggesting the promising applications of LS-ARS2 for combating pathogenic biofilms and improving gut-health. However, further in vivo studies would facilitate their potential applications.


  • Open Access

    Complete Genome Sequence, Metabolic Profiling and Functional Studies reveal Ligilactobacillus salivarius LS-ARS2 is a Promising Biofilm-forming Probiotic with Significant Antioxidant, Antibacterial, and Antibiofilm Potential

    by Sinjini Patra, Biswaranjan Pradhan, Anasuya Roychowdhury

    BACKGROUND: Probiotics restore microbial balance and prevent gut-inflammation. Therefore, finding out novel probiotic strains is a demand. As gut-microbe, benefits of Ligilactobacillus salivarius (LS) are established. However, strain-specific detailed studies are limited. Here, we illustrate probiotic attributes of novel LS-ARS2 for its potential application as food-supplement and/or therapeutic to improve gut-health. METHODS: Whole genome sequencing (WGS) and phylogenetic analysis confirm the strain as LS . To establish probiotic properties, acid-bile tolerance, auto-aggregation, cell-surface-hydrophobicity, biofilm-formation and adhesion-assays are performed. To ensure safety attributes, antibiotic-susceptibility, haemolytic, DNase, trypan-blue and MTT assays are done. ABTS, DPPH, superoxide, hydroxyl free radical scavenging assays are used to determine anti-oxidant potential. Antibacterial assays including co-culture assay with pathogen and pathogenic biofilm-inhibition assays are performed to explore antibacterial efficacy. To characterize metabolic-profile of LS-ARS2 -derived cell-free-supernatant (CFS), HRMS analysis are carried out. Consequently, WGS-analyses predict potential molecular associations related to functional outcomes. RESULTS: We find LS-ARS2 as remarkable fast-growing strain that shows acid and bile tolerance (>60% survival rate) indicating promising gut-sustainability. High auto-aggregation capacity (>80%), robust cell-surface hydrophobicity (>85%), and adhesion efficacy to Caco-2 cells illustrate significant potential of LS-ARS2 for gut colonization. Fascinatingly, LS-ARS2 is able to form biofilm within 24 h (p60%), DPPH (>10U/mL), superoxide (>70%), and hydroxyl free radical scavenging assays (>70%). Further, LS-ARS2 shows antimicrobial activities against Gram-positive Methicillin-resistant Staphylococcus aureus (MRSA) and Gram-negative multidrug-resistant clinical strains enterotoxigenic Escherichia coli, Vibrio cholerae, and Shigella flexneri . Anti- Salmonella effect of LS-ARS2 is prominent (pLS-ARS2 -CFS inhibits MRSA -biofilm (pLS strains. CONCLUSIONS LS-ARS2 is a novel fast-growing, biofilm-forming probiotic with significant antioxidant, antibacterial, and anti-biofilm potentials, suggesting the promising applications of LS-ARS2 for combating pathogenic biofilms and improving gut-health. However, further in vivo studies would facilitate their potential applications.

  • ATAD2 suppression enhances the combinatorial effect of gemcitabine and radiation in pancreatic cancer cells

    by Madhuri Dutta, Debasish Mohapatra, Amlan Priyadarshee Mohapatra, Shantibhusan Senapati, Anasuya Roychowdhury


  • Open Access

    Abstract 5680: Hypoxia-responsive and HIF1α-regulated AAA+ ATPase ATAD2 shows high oncogenic potential in stomach cancer

    by Anasuya Roychowdhury, Aditi Nayak, Sugandh Kumar, Anshuman Dixit, Asima Bhattacharyya

    The burden of stomach cancer incidence and death is a global challenge. Treating stomach cancer remains immensely difficult due to the lack of available markers to detect the disease at the early stages. Therefore, there is an immense demand for finding out an early detection biomarker for stomach cancer. Recently, ATAD2 is found to be overexpressed in stomach cancer with high prognostic significance and recognised as a promising biomarker for stomach cancer. ATAD2 is a unique cancer/testis antigen (CTA) that belongs to both AAA+ ATPase and bromodomain family proteins. However, nothing much is known about the mechanism of ATAD2-mediated stomach carcinogenesis. Using bioinformatics analyses as well as studies with stomach cancer cells and stomach biopsy tissue samples, we address the regulation and function of ATAD2 expression in stomach cancer. We show that ATAD2 is overexpressed in the most common intestinal type of stomach adenocarcinoma, and enhanced expression of ATAD2 is observed in all stages and grades of stomach cancer. Our immunofluorescence microscopy study with stomach biopsy tissues confirms the high expression of ATAD2 both in stomach adenocarcinoma and metastatic stomach tissue samples. Survival analysis indicates that upregulated ATAD2 expression drastically affects the survival of stomach cancer patients. Since H. pylori infection, and hypoxia are the major contributing factors for stomach carcinogenesis; we further study their role in ATAD2-mediated stomach malignancy. An enhanced expression of ATAD2 is observed in H. pylori-infected stomach cancer cells. We identify ATAD2 as a hypoxia-responsive and HIF1α-regulated gene and elucidate that upregulated expression of ATAD2 enhances proliferation and migration of hypoxic stomach cancer cells. We further recognize the protein-protein interaction (PPI) network of ATAD2 with the top-ranked partners like ESR1 (or ERα), NCOA3 (or ACTR/SRC3/AIB1), SUMO2, HDA11 (HDAC11), SPTN2 (SPTBN2), and MYC. Among them, ESR1, MYC, NCOA3, and HDA11 are oncoproteins. Most strikingly, we report the participation of two druggable targets of ATAD2, i.e., AAA+ ATPase and bromodomain in the ATAD2-PPI network; ESR1, SUMO2, SPTN2, and MYC show a preference for bromodomain, whereas NCOA3 and HDA11 prefer ATPase domain of ATAD2. The importance of such findings in terms of targeting bromodomain-PPI and/or ATPase-PPI interfaces to curtail stomach cancer is elucidated. Citation Format: Anasuya Roychowdhury, Aditi Nayak, Sugandh Kumar, Anshuman Dixit, Asima Bhattacharyya. Hypoxia-responsive and HIF1α-regulated AAA+ ATPase ATAD2 shows high oncogenic potential in stomach cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5680.

  • MicroRNA-217 modulates pancreatic cancer progression via targeting ATAD2

    by Madhuri Dutta, Biswajit Das, Debasish Mohapatra, Padmanava Behera, Shantibhusan Senapati, Anasuya Roychowdhury


  • Emerging oncogene ATAD2: Signaling cascades and therapeutic initiatives

    by Aditi Nayak, Madhuri Dutta, Anasuya Roychowdhury


  • Systematic Network and Meta-analysis on the Antiviral Mechanisms of Probiotics: A Preventive and Treatment Strategy to Mitigate SARS-CoV-2 Infection

    by Sinjini Patra, Shivam Saxena, Nilanjan Sahu, Biswaranjan Pradhan, Anasuya Roychowdhury

    With the alarming rise of infected cases and deaths, COVID-19 is a pandemic, affecting 220 countries worldwide. Until now, no specific treatment is available against SARS-CoV-2. The causal virus SARS-CoV-2 primarily infects lung cells, leading to respiratory illness ranging in severity from the common cold to deadly pneumonia. This, with comorbidities, worsens the clinical outcome, particularly for immunosuppressed individuals with COVID-19. Interestingly, the commensal gut microbiota has been shown to improve lung infections by modulating the immune system. Therefore, fine-tuning of the gut microbiome with probiotics could be an alternative strategy for boosting immunity and treating COVID-19. Here, we present a systematic biological network and meta-analysis to provide a rationale for the implementation of probiotics in preventing and/or treating COVID-19. We have identified 90 training genes from the literature analysis (according to PRISMA guidelines) and generated an association network concerning the candidate genes linked with COVID-19 and probiotic treatment. The functional modules and pathway enrichment analysis of the association network clearly show that the application of probiotics could have therapeutic effects on ACE2-mediated virus entry, activation of the systemic immune response, nlrp3-mediated immunomodulatory pathways, immune cell migration resulting in lung tissue damage and cardiovascular difficulties, and altered glucose/lipid metabolic pathways in the disease prognosis. We also demonstrate the potential mechanistic domains as molecular targets for probiotic applications to combat the viral infection. Our study, therefore, offers probiotics-mediated novel preventive and therapeutic strategies for COVID-19 warfare.